Annovis Bio, Inc. (ANVS)

Market Cap	60.29M
Revenue (ttm)	n/a
Net Income (ttm)	-40.94M
Shares Out	13.80M
EPS (ttm)	-3.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	329,533
Open	4.460
Previous Close	4.400
Day's Range	4.310 - 4.530
52-Week Range	4.310 - 22.490
Beta	1.59
Analysts	Strong Buy
Price Target	29.67 (+578.95%)
Earnings Date	Nov 8, 2024

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 29, 2020
• Employees: 16
• Stock Exchange: NYSE
• Ticker Symbol: ANVS
• Website: https://www.annovisbio.com

Analyst Forecast

According to 6 analysts, the average rating for ANVS stock is "Strong Buy." The 12-month stock price forecast is $29.67, which is an increase of 578.95% from the latest price.

Price Target

$29.67

(578.95% upside)

Analyst Consensus: Strong Buy